{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:13:22Z","timestamp":1791317602162,"version":"4.3.1"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Sanofi and ActoBio Therapeutics"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,1,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Islet cell-specific autoantibodies are useful to classify diabetes. The aim of this study was to evaluate the performance of commercially available ELISAs to detect autoantibodies to glutamic acid decarboxylase 65-kDa isoform (GADA), tyrosine phosphatase-related islet antigen 2 (IA-2A), zinc transporter protein 8 (ZnT8A), and insulin (IAA). The performance of ELISA was compared to the performance of RIA.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We retrospectively identified 76 newly diagnosed type 1 diabetes mellitus patients (median age 27\u2009years, female\/male: 0.65) and 131 disease controls (median age 45\u2009years, female\/male: 0.60). The ELISAs were from Medipan. RIAs were in-house methods from the Belgian Diabetes Registry or from Medipan or DIASource.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Sensitivity and specificity of ELISA were, respectively, 97% and 97% for GADA, 61% and 99% for IA-2A, 1% and 96% for IAA, and 70% and 98% for ZnT8A. The likelihood ratio for type 1 diabetes increased with increasing antibody levels for GADA, IA-2A, and ZnT8A measured by ELISA. The positive predictive value of double positivity for either GADA, IA-2A, or ZnT8A was 100%.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The ELISAs to detect GADA, IA-2A, and ZnT8A have good performance characteristics. Combining autoantibody assays and taking into account antibody levels improves the interpretation of autoantibody testing.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jalm\/jfab141","type":"journal-article","created":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T11:13:19Z","timestamp":1635246799000},"page":"66-74","source":"Crossref","is-referenced-by-count":7,"title":["Pancreas Islet Cell-Specific Antibody Detection by ELISA"],"prefix":"10.1093","volume":"7","author":[{"given":"Sophie","family":"Van Aelst","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine, Heilig-Hart Hospital Lier, Lier, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9111-4561","authenticated-orcid":false,"given":"Pieter","family":"Gillard","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, University Hospitals Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilse","family":"Weets","sequence":"additional","affiliation":[{"name":"Department of Clinical Chemistry and Radioimmunology, Brussels Free University, Elsene, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doreen","family":"Dillaerts","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, KU Leuven\u2014University of Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaak","family":"Billen","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, University Hospitals Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4055-5233","authenticated-orcid":false,"given":"Chantal","family":"Mathieu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, University Hospitals Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Bossuyt","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, KU Leuven\u2014University of Leuven, Leuven, Belgium"},{"name":"Department of Laboratory Medicine, University Hospitals Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,1,5]]},"reference":[{"key":"2022010916495209800_jfab141-B1","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.2337\/dc19-S002","article-title":"Classification and diagnosis of diabetes: standards of medical care in diabetes","volume":"42","year":"2019","journal-title":"Diabetes Care"},{"key":"2022010916495209800_jfab141-B2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1210\/jc.2009-1365","article-title":"Clinical applications of diabetes antibody testing","volume":"95","author":"Bingley","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"2022010916495209800_jfab141-B3","doi-asserted-by":"crossref","first-page":"926","DOI":"10.2337\/diab.45.7.926","article-title":"Prediction of type 1 diabetes in first-degree relatives using a combination of insulin, GAD, ICA512bdc\/IA-2 autoantibodies","volume":"45","author":"Verge","year":"1996","journal-title":"Diabetes"},{"key":"2022010916495209800_jfab141-B4","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s00125-003-1123-7","article-title":"Multiple autoantibodies as predictors of type 1 diabetes in a general population","volume":"46","author":"Maclaren","year":"2003","journal-title":"Diabetologia"},{"key":"2022010916495209800_jfab141-B5","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s00125-009-1618-y","article-title":"Predictive power of screening for antibodies against insulinoma-associated protein 2 beta (IA-2 \u03b2) and zinc transporter-8 to select first-degree relatives of type 1 diabetic patients with risk of rapid progression to clinical onset of the disease: implications for prevention trials","volume":"53","author":"De Grijse","year":"2010","journal-title":"Diabetologia"},{"key":"2022010916495209800_jfab141-B6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s001250051105","article-title":"Autoantigens IA-2 and GAD in type 1 (insulin dependent) diabetes","volume":"42","author":"Leslie","year":"1999","journal-title":"Diabetologia"},{"key":"2022010916495209800_jfab141-B7","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1007\/s00125-002-0949-8","article-title":"IA-2 autoantibodies predict impending type 1 diabetes in siblings of patients","volume":"45","author":"Decochez","year":"2002","journal-title":"Diabetologia"},{"key":"2022010916495209800_jfab141-B8","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1172\/JCI119879","article-title":"Prediction of insulin-dependent diabetes mellitus in siblings of children with diabetes","volume":"101","author":"Kulmala","year":"1998","journal-title":"J Clin Invest"},{"key":"2022010916495209800_jfab141-B9","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1001\/jama.2013.6285","article-title":"Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children","volume":"309","author":"Ziegler","year":"2013","journal-title":"JAMA"},{"key":"2022010916495209800_jfab141-B10","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s00125-006-0160-4","article-title":"Progression to type 1 diabetes in islet cell antibody-positive relatives in the European nicotinamide diabetes intervention trial: the role of additional immune, genetic and metabolic markers of risk","volume":"49","author":"Bingley","year":"2006","journal-title":"Diabetologia"},{"key":"2022010916495209800_jfab141-B11","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1365-2249.2012.04675.x","article-title":"Belgian Diabetes Registry, Screening for insulinoma antigen 2 and zinc transporter 8 autoantibodies: a cost-effective and age-independent strategy to identify rapid progressors to clinical onset among relatives of type 1 diabetic patients","volume":"171","author":"Gorus","year":"2013","journal-title":"Clin Exp Immunol"},{"key":"2022010916495209800_jfab141-B12","doi-asserted-by":"crossref","first-page":"57e1","DOI":"10.1373\/clinchem.2011.163634","article-title":"Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus","volume":"57","author":"Sacks","year":"2011","journal-title":"Clin Chem"},{"key":"2022010916495209800_jfab141-B13","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.2337\/diabetes.54.suppl_2.S52","article-title":"Autoantibodies in diabetes","volume":"54","author":"Pihoker","year":"2005","journal-title":"Diabetes"},{"key":"2022010916495209800_jfab141-B14","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1172\/JCI118188","article-title":"Relationship of the 37,000- and 47,000 Mr tryptic fragments of islet antigens in insulin-dependent diabetes to the protein tyrosine phosphatase-like molecule IA-2 (ICA512)","volume":"96","author":"Payton","year":"1995","journal-title":"J Clin Invest"},{"key":"2022010916495209800_jfab141-B15","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1007\/BF00401060","article-title":"Insulin autoantibodies and high titre islet cell antibodies are preferentially associated with the HLA DQA10301-DQB10302 haplotype at clinical onset of Type 1 (insulin-dependent) diabetes mellitus before age 10 years, but not at onset between age 10 and 40 years","volume":"36","author":"Vandewalle","year":"1993","journal-title":"Diabetologia"},{"key":"2022010916495209800_jfab141-B16","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s001250050648","article-title":"IA-2-autoantibodies complement GAD65-autoantibodies in new-onset IDDM patients and help predict impending diabetes in their siblings","volume":"40","author":"Gorus","year":"1997","journal-title":"Diabetologia"},{"key":"2022010916495209800_jfab141-B17","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1007\/s00125-008-0967-2","article-title":"Diabetes antibody standardization program: evaluation of assays for autoantibodies to glutamic acid decarboxylase and islet antigen-2","volume":"51","author":"T\u00f6rn","year":"2008","journal-title":"Diabetologia"},{"key":"2022010916495209800_jfab141-B18","doi-asserted-by":"crossref","first-page":"17040","DOI":"10.1073\/pnas.0705894104","article-title":"The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes","volume":"104","author":"Wenzlau","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"2022010916495209800_jfab141-B19","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1007\/s00125-010-1915-5","article-title":"Diabetes antibody standardization program: evaluation of assays for insulin autoantibodies","volume":"53","author":"Schlosser","year":"2010","journal-title":"Diabetologia"},{"key":"2022010916495209800_jfab141-B20","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1373\/clinchem.2011.170662","article-title":"Diabetes antibody standardization program: first proficiency evaluation of assays for autoantibodies to zinc transporter 8","volume":"57","author":"Lampasona","year":"2011","journal-title":"Clin Chem"},{"key":"2022010916495209800_jfab141-B21","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1373\/clinchem.2019.304196","article-title":"Islet Autoantibody Standardization Program 2018 Workshop: interlaboratory comparison of glutamic acid decarboxylase autoantibody assay performance","volume":"65","author":"Lampasona","year":"2019","journal-title":"Clin Chem"},{"key":"2022010916495209800_jfab141-B22","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.2337\/diabetes.47.12.1857","article-title":"Combined use of autoantibodies (IA-2 autoantibody, GAD autoantibody, insulin autoantibody, cytoplasmic islet cell antibodies) in type 1 diabetes: combinatorial islet autoantibody workshop","volume":"47","author":"Verge","year":"1998","journal-title":"Diabetes"},{"key":"2022010916495209800_jfab141-B23","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1073\/pnas.040556697","article-title":"Early expression of antiinsulin autoantibodies of humans and the NOD mouse: evidence for early determination of subsequent diabetes","volume":"97","author":"Yu","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"2022010916495209800_jfab141-B24","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.2337\/diabetes.51.5.1346","article-title":"Genetic effects on age-dependent onset and islet cell autoantibody markers in type 1 diabetes","volume":"51","author":"Graham","year":"2002","journal-title":"Diabetes"},{"key":"2022010916495209800_jfab141-B25","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s005920050072","article-title":"Islet autoantibodies and their use in predicting insulin-dependent diabetes","volume":"34","author":"Bonifacio","year":"1997","journal-title":"Acta Diabetol"},{"key":"2022010916495209800_jfab141-B26","doi-asserted-by":"crossref","first-page":"736","DOI":"10.2337\/diacare.11.9.736","article-title":"Concentration of insulin autoantibodies at onset of type 1 diabetes. Inverse log-linear correlation with age","volume":"11","author":"Vardi","year":"1988","journal-title":"Diabetes Care"},{"key":"2022010916495209800_jfab141-B27","first-page":"846","article-title":"High diagnostic sensitivity of glutamate decarboxylase autoantibodies in insulin-dependent diabetes mellitus with clinical onset between age 20 and 40 years. The Belgian Diabetes Registry","volume":"80","author":"Vandewalle","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"2022010916495209800_jfab141-B28","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1007\/s00125-015-3514-y","article-title":"The 6 year incidence of diabetes-associated autoantibodies in genetically at-risk children: the TEDDY study","volume":"58","author":"Krischer","year":"2015","journal-title":"Diabetologia"},{"key":"2022010916495209800_jfab141-B29","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1007\/s00125-017-4308-1","article-title":"Early prediction of autoimmune (type 1) diabetes","volume":"60","author":"Regnell","year":"2017","journal-title":"Diabetologia"},{"key":"2022010916495209800_jfab141-B30","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.2337\/dc16-2228","article-title":"Twenty-year progression rate to clinical onset according to autoantibody profile, age, and HLA-DQ genotype in a registry-based group of children and adults with a first-degree relative with type 1 diabetes","volume":"40","author":"Gorus","year":"2017","journal-title":"Diabetes Care"},{"key":"2022010916495209800_jfab141-B31","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.2337\/dc10-2268","article-title":"Contribution of antibodies against IA-2\u03b2 and zinc transporter 8 to classification of diabetes diagnosed under 40 years of age","volume":"34","author":"Vermeulen","year":"2011","journal-title":"Diabetes Care"},{"key":"2022010916495209800_jfab141-B32","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1007\/s00125-015-3672-y","article-title":"Islet autoantibody phenotypes and incidence in children at increased risk for type 1 diabetes","volume":"58","author":"Giannopoulou","year":"2015","journal-title":"Diabetologia"},{"key":"2022010916495209800_jfab141-B33","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.2337\/diacare.20.9.1403","article-title":"Evaluation of ICA512As in combination with other islet cell autoantibodies at the onset of IDDM","volume":"20","author":"Feeney","year":"1997","journal-title":"Diabetes Care"},{"key":"2022010916495209800_jfab141-B34","year":"2019"}],"container-title":["The Journal of Applied Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jalm\/article-pdf\/7\/1\/66\/42084016\/jfab141.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jalm\/article-pdf\/7\/1\/66\/42084016\/jfab141.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,9]],"date-time":"2022-01-09T16:51:31Z","timestamp":1641747091000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jalm\/article\/7\/1\/66\/6498253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,1]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1,5]]},"published-print":{"date-parts":[[2022,1,5]]}},"URL":"https:\/\/doi.org\/10.1093\/jalm\/jfab141","relation":{},"ISSN":["2576-9456","2475-7241"],"issn-type":[{"value":"2576-9456","type":"print"},{"value":"2475-7241","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,1,1]]},"published":{"date-parts":[[2022,1,1]]}}}